Clinical Trial Update: Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating belzutifan for indolent metastatic clear cell renal cell carcinoma, comparing active surveillance with treatment; the study is not ye…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• Welireg (belzutifan)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Active Surveillance, Clear Cell Renal Cell Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING